Antiviral drugs for patients with chronic hepatitis B include two categories: Interferons and nucleoside (acid) analogues. At present, five oral nucleoside (acid) analogues are listed in China: entecavir (ETV), tenofovir dipivoxil (TDF), telbivudine (LDT), adefovir dipivoxil (ADV) and lamivudine (LAM). Entecavir is one of the first-line antiviral drugs recommended by the World Health Organization and national guidelines for patients with chronic hepatitis B.
It is used to treat chronic adult hepatitis B with active virus replication, continuous increase of serum alanine aminotransferase (ALT) or active liver histology.
1. Entecavir is not a substrate, inhibitor or inducer of cytochrome P450 enzyme system and does not inhibit any major human cytochrome P450 enzymes (1A2, 2C9, 2c19, 2d6, 3A4, 2b6 and 2E1).
2. Entecavir is mainly cleared through the kidney. While taking drugs that reduce renal function or competitive secretion through active glomerulus, taking entecavir may increase the blood concentration of these two drugs.